Apr 18, 2017 Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells Learn More
Apr 12, 2017 Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Learn More
Apr 10, 2017 Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors Learn More
Mar 30, 2017 After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Learn More